The Sinovac vaccine will start to be applied from this Saturday, confirmed Marcelo Ebrard

The CoronaVac vaccine, from Chinese laboratory Sinovac, will begin to be applied from this Saturday, as well as the assets of Pfizer and AstraZeneca, Mexican Foreign Minister Marcelo Ebrard reported., while announcing that a total of 10 million doses of the Chinese vaccine will arrive in our country in the coming weeks.

Via your account Twitter, Ebrard wrote: “The 200,000 doses of the Sinovac vaccine have arrived from Hong Kong. As of today, Mexico will apply the Pfizer, AstraZeneca and Sinovac vaccines. In total, 10 million doses of this vaccine will arrive in the coming weeks ”.

In a second tweet, Ebrard Casaubón thanked Chinese Ambassador Zhu Qingqiao. “Thank you Ambassador Zhu Qingqiao for responding to President Lopez Obrador’s call who, still ill with Covid19, led the effort to have this news. Mexico will always remember your support and that of China at this difficult time. Thank you !!, wrote the Mexican Minister of Foreign Affairs.

Later, Marcelo Ebrard posted an image that reads the following message in Chinese and Spanish: “Mexico thanks the people and government of the People’s Republic of China for their solidarity and cooperation in difficult times. We are and always will be friendly peoples, a text signed by the Government of Mexico and the Ministry of Foreign Affairs.

This morning, the first shipment of 200,000 vaccines arrived from Sinovac at Mexico City International Airport, which was received by Martha Delgado, Undersecretary for Multilateral Affairs and Human Rights of the Ministry of Foreign Relations (SRE), the Chinese Ambassador to Mexico, Zhu Qingqiao; the Director General of the ISSSTE, Luis Antonio Ramirez and the surgeon and homeopath of the (National Polytechnic Institute (IPN), Pedro Zenteno Santaella.

Since the afternoon of Friday February 19, the Mexican Minister of Foreign Affairs Marcelo Ebrard reported the arrival in Mexico of the first 200,000 doses of the Sinovac vaccine, while specifying that it was a donation. from the Chinese government.

Mexican President Andrés Manuel López Obrador argued last Tuesday that there was already an agreement for the first million vaccines.

“Sinovac will conclude the agreement for 1 million vaccines next Monday. Of these vaccines, we will use 200 first and the remaining 800,000 will have to be paid for, ”he said at his morning press conference.

CoronaVac is a chemically inactivated version of the SARS-CoV-2 virus, which causes COVID-19. It is different from other vaccines such as the one developed by Pfizer-BioNTech, which occupies strands of viral DNA to signal the cells of the vaccinated person to produce SARS-CoV-2 virus proteins which are then detected by the system. immune system that develops. defenses against the virus.

In the case of CoronaVac, a “traditional” method is used in which an inactive and safe version of the virus is introduced into the body of the vaccinated person so that the immune system recognizes it and builds the defenses to fight the disease.

Based on the results of phase 1 and 2 clinical trials to assess the safety, tolerability and ability of the vaccine to elicit an immune response in humans, the vaccine is able to protect against COVID-19 without producing serious adverse reactions. For phase 2, a group of 118 people received 6 micrograms of the drug, with a second dose at 28 days. The results revealed a robust immune response: all 118 people vaccinated generated antibodies against the SARS-CoV-2 virus.

In addition, the same study also showed that CoronaVac can produce a sufficient immune response if the second dose of the vaccine is given within 14 days of the first.

En cuanto a los efectos secundarios, el gobierno brasileño, país donde están llevando a cabo los ensayos clínicos de fase 3, revealed that tras la primera dosis, sólo el 19% presentó dolor local en la zona de la inyección y 15% dolor de Head.

After the second dose, the Butantan Institute, which is conducting phase 3 clinical trials for CoronaVac, again reported 19% on local pain, 10% of people had headaches, 4% of people suffered from fatigue and only 0.1% had a low fever.

MORE ON THIS TOPIC: